London
· Delayed Price · Currency is GBP · Price in EUR PHAXIAM Therapeutics Company Description
PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States.
It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients.
The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa.
The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023.
PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.
| Country | France |
| Founded | 2004 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 68 |
| CEO | Thibaut Fayet |
Contact Details
Address: 60 Avenue Rockefeller Lyon, 69008 France | |
| Phone | 33 4 78 74 44 38 |
| Website | phaxiam.com |
Stock Details
| Ticker Symbol | 0QSS |
| Exchange | London Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| ISIN Number | FR001400K4B1 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Gil Beyen BVBA | Chief Executive Officer and Director |
| Eric Soyer Ph.D. | Deputy GM, Chief Financial Officer and Chief Operating Officer |
| Dr. Jérôme Bailly Pharm.D. | Deputy GM of Operations, Chief Quality Officer and Qualified Person |
| Naomi Eichenbaum | Director Investor Relations |
| Brian Schwab | Chief Legal Officer and General Counsel |
| Anne-Cécile Fumey | HR Director |
| Dr. Iman El-Hariry M.D., Ph.D. | Chief Medical Officer |
| Dr. Philip L. Lorenzi | Consultant and Member of Scientific Board |
| Prof. Eric Raymond M.D., Ph.D. | Consultant and Member of Scientific Board |
| Dr. Bridget Bax | Consultant and Member of Scientific Board |